Stiripentol

Mechanism :

Exact mechanism is not known. May enhance GABAergic inhibitory neurotransmission by weak partial agonism and/or positive allosteric modulation of gamma-aminobutyric acid (GABA)-A receptors. It also inhibits multiple cytochrome P450 isoenzymes involved in the metabolism of other anticonvulsants

Indication :

• Dravet syndrome: Adjunctive treatment in conjunction with clobazam and valproic acid in patients with severe myoclonic epilepsy in infancy.

Contraindications :

Hypersensitivity to stiripentol or any component of the formulation.

Dosing :

Adverse Effect :

Drowsiness, agitation, ataxia, hypotonia, dysarthria, insomnia, weight loss/gain, decreased appetite, nausea, thrombocytopenia, neutropenia, tremor, fatigue, vomiting, sialorrhea, fever.

Interaction :

Caffeine and Caffeine Containing Products: Stiripentol may increase the serum concentration of Caffeine and Caffeine Containing Products.
Carbamazepine: Stiripentol may increase the serum concentration of Carbamazepine.
CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.
CYP1A2 Inducers: May decrease the serum concentration of CYP1A2 Substrates
CYP1A2 Inhibitors: May decrease the metabolism of CYP1A2 Substrates
CYP1A2 Substrates: CYP1A2 Inhibitors may decrease the metabolism of CYP1A2 Substrates.
CYP2C19 Inducers: May increase the metabolism of CYP2C19 Substrates
CYP2C19 Inhibitors: May decrease the metabolism of CYP2C19 Substrates
CYP3A4 Inducers: May increase the metabolism of CYP3A4 Substrates
CYP3A4 Inhibitors: May decrease the metabolism of CYP3A4 Substrates
CYP3A4 Substrates: Stiripentol may increase the serum concentration of CYP3A4 Substrates
Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.
Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.

Hepatic Dose :